Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study.
Study Goal
The researchers aimed to determine whether oral supplementation with CoQ10 (Q-ter) and creatine could improve exercise tolerance and quality of life in patients with chronic heart failure (CHF) by addressing mitochondrial dysfunction.
Results Summary
The study found that the active treatment group (Q-ter + creatine) showed a significant improvement in peak oxygen consumption (VO2) compared to placebo, suggesting a beneficial effect on physical performance in stable systolic CHF. No adverse effects were reported in either group.
Population
Patients with stable CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 35%).
Effective Dosage
Q-ter 320 mg + creatine 340 mg once daily.
Duration
8 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Oral supplementation with coenzyme Q(10) (CoQ(10)) and creatine | decrease | mitochondrial dysfunction that contributes to impaired physical performance | patients with chronic heart failure (CHF) | - | may reduce | #1 |
a mixture of water-soluble CoQ(10) (CoQ(10) terclatrate; Q-ter) and creatine | neutral | exercise tolerance and health-related quality of life | patients with CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 35%) | - | determine the effect | #2 |
Q-ter 320 mg + creatine 340 mg | increase | 8-week peak VO(2) | patients with stable CHF | +1.8 ± 0.9 mL/min/kg, 95% CI: 0.1-3.6 | significantly higher | #3 |
Q-ter 320 mg + creatine 340 mg | no change | safety | patients with stable CHF | - | No untoward effects occurred | #4 |
oral Q-ter and creatine, added to conventional drug therapy | increase | physical performance | patients with stable systolic CHF | - | exert some beneficial effect | #5 |
BACKGROUND: Studies have suggested that micronutrient deficiency has some role in the progression of chronic heart failure (CHF). HYPOTHESIS: Oral supplementation with coenzyme Q(10) (CoQ(10)) and creatine may reduce mitochondrial dysfunction that contributes to impaired physical performance in CHF. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to determine the effect of a mixture of water-soluble CoQ(10) (CoQ(10) terclatrate; Q-ter) and creatine on exercise tolerance and health-related quality of life. Exercise tolerance was measured as total work capacity (kg·m) and peak oxygen consumption (VO(2), mL/min/kg), both from a cardiopulmonary exercise test. Health-related quality of life was measured by the Sickness Impact Profile (SIP) in CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 35%). After baseline assessment, 67 patients with stable CHF were randomized to receive Q-ter 320 mg + creatine 340 mg (n = 35) or placebo (n = 32) once daily for 8 weeks. RESULTS: At multivariate analysis, 8-week peak VO(2) was significantly higher in the active treatment group than in the placebo group (+1.8 ± 0.9 mL/min/kg, 95% CI: 0.1-3.6, P < 0.05). No untoward effects occurred in either group. CONCLUSIONS: This study suggests that oral Q-ter and creatine, added to conventional drug therapy, exert some beneficial effect on physical performance in stable systolic CHF. Results may support the design of larger studies aimed at assessing the long-term effects of this treatment on functional status and harder outcomes.